A Possible Therapeutic Role for Adenosine During Inflammation

Status Completed

Clinical Trial Summary

The adenosine receptor is known for its anti-inflammatory actions and could therefore be a potential target in the treatment of sepsis and septic shock. Stimulation of the adenosine receptor could potentially lead to a decrease in inflammation and tissue damage.

Under normal conditions adenosine is formed either by an intracellular 5`nucleotidase, which dephosphorylates AMP, or by the hydrolysis of S-adenosylhomcysteine by hydrolase. An alternative pathway of AMP degradations is provided by the cytosolic enzyme AMP deaminase (AMPD), which catalyses the irreversible deamination of AMP to inosine monophosphate and ammonia.

In humans four AMPD isoforms have been described, named after the source from which they were initially purified; M (muscle), L (liver), E1 and E2 (erythrocyte), encoded by AMPD1, AMPD2 and AMPD3. Approximately 15-20% of Caucasian and African American individuals are heterozygous or homozygous for the 34C>T variant of AMPD1.

We hypothesize that healthy volunteers who have the polymorphism for AMPD1 have a less severe inflammatory response to LPS and show less (severe) organ failure. This hypothesis is based on the expected higher levels of adenosine in patients with the AMPD1 polymorphism. This hypothesis is strengthened by the fact that patients with coronary artery disease and the AMPD1 polymorphism show improved cardiovascular survival (Anderson JL et al. J Am Coll Cardiol 2000; 36: 1248-52) possibly based on higher adenosine levels by reduced AMPD activity. Furthermore the polymorphism predicts improved clinical outcome in patients with heart failure (Loh E et al. Circulation 1999) also based on a hypothetical elevation of adenosine.

We hypothesize that:

The C34T-polymorphism of the enzyme AMP-deaminase leads to a decreased inflammatory respons and thereby a decrease of LPS-induced tissue damage.

A second hypothesis is based on the antagonism of the adenosine receptor, by caffeine;

Antagonism of the adenosine receptor by caffeine leads to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissue damage?

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Endotoxemia

Clinical Trial Details

NCT number	NCT00513110
Study type	Interventional
Source	Radboud University
Contact
Status	Completed
Phase	Phase 1
Start date	August 2007
Completion date	August 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT02922673` - The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia	N/A
Completed	`NCT01766414` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II	Phase 3
Completed	`NCT04130321` - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans	N/A
Completed	`NCT02612480` - Ticagrelor in Human Endotoxemia Response to Human Endotoxemia	N/A
Completed	`NCT01474629` - Probiotic Sport Study	N/A
Completed	`NCT00246714` - Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans	Phase 1
Recruiting	`NCT06147440` - Different Dietary Patterns	N/A
Recruiting	`NCT03901807` - Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study	N/A
Completed	`NCT03754504` - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT03800277` - Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health	N/A
Completed	`NCT00785018` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia	N/A
Recruiting	`NCT00413465` - Study of Renal Blood Flow During Human Endotoxemia	N/A
Recruiting	`NCT00413348` - Type 2 Diabetes and the Effect of Probiotics	N/A
Completed	`NCT00412906` - Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls	N/A
Completed	`NCT05752968` - Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
Completed	`NCT01374711` - The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia	N/A
Completed	`NCT00916448` - The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia	N/A
Completed	`NCT00332267` - Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia	N/A
Completed	`NCT03482284` - Effect of Monosaccharides on Intestinal Barrier Function	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.